ŠObesity and it’s associated comorbidities is increasing.
ŠWeight loss drugs provide a modest reduction in body
weight (<5kg at 1 year); weight regain is common.
ŠImprovements in metabolic risk factors may be seen.
{e.g. ↓ progression to diabetes with orlistat in those with IGT}
ŠLong-term efficacy, safety and outcome data is lacking.
ŠPrescription, herbal and OTC agents used for weight
loss are expensive. The 2 drugs with official weight
loss indications, Sibutramine MERIDIA and Orlistat
XENICAL, cost >$120 per month. (Neither are
currently covered by the SK formulary or NIHB.)
ŠConsider cardiovascular risk reduction strategies such
as lifestyle interventions and drugs such as ASA,
antihypertensives and statins if indicated.
ŠMinimizing weight gain may be a consideration when
choosing drugs within certain therapeutic classes.
_______________________________________________
IGT= impaired glucose tolerance; OTC=over the counter products;
SK=Saskatchewan; NIHB=Indian Affairs
